Charaschanya Manwika, Maskrey Taber S, LaPorte Matthew G, Janjic Jelena M, Wipf Peter
Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.
Pharmaceutical Sciences, Duquesne University School of Pharmacy, 415 Mellon Hall, Pittsburgh, Pennsylvania 15282, United States.
ACS Med Chem Lett. 2022 Feb 4;13(3):403-408. doi: 10.1021/acsmedchemlett.1c00561. eCollection 2022 Mar 10.
JP4-039 is an alkene peptide isostere that acts as a low-micromolar inhibitor of erastin- and RSL-3-induced ferroptotic cell death in the HT-1080 cell line. In this work, we have developed new synthetic strategies that allow access to analogues of this lead structure. Enantioselective vinylogous Mannich or cross-metathesis reactions were key to the preparation of a series of analogues that culminated in the preparation of the 30-fold more potent analogue ()-. Structure-activity relationship analyses used both HT-1080 cells and a luminescence-based ferroptosis assay in RAW 264.7 macrophages. In particular, α,α-disubstituted alkene peptide isosteres (R ≠ H) were found to exceed the potency of the corresponding glycine (R = H) derivatives.
JP4-039是一种烯烃肽类似物,在HT-1080细胞系中,它作为一种低微摩尔浓度的抑制剂,可抑制埃拉斯汀和RSL-3诱导的铁死亡细胞死亡。在这项工作中,我们开发了新的合成策略,从而能够获得这种先导结构的类似物。对映选择性乙烯基曼尼希反应或交叉复分解反应是制备一系列类似物的关键,最终制备出了活性强30倍的类似物()-。构效关系分析使用了HT-1080细胞以及RAW 264.7巨噬细胞中基于发光的铁死亡检测方法。特别地,发现α,α-二取代烯烃肽类似物(R ≠ H)的活性超过了相应的甘氨酸(R = H)衍生物。